Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 2
1986 3
1991 3
1992 3
1996 1
1997 1
1998 1
1999 3
2000 6
2001 5
2002 8
2003 8
2004 11
2005 9
2006 7
2007 12
2008 13
2009 10
2010 8
2011 10
2012 11
2013 16
2014 21
2015 22
2016 15
2017 14
2018 20
2019 19
2020 18
2021 15
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

269 results
Results by year
Filters applied: . Clear all
Page 1
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Bétard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R; EBOVAC2 EBL2001 study group. Pollard AJ, et al. Among authors: richert l. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217361 Clinical Trial.
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R, Journot V, Nguyen D, Peiffer-Smadja N, Crémer A, Bouchet S, Darnaud T, Poitrenaud D, Piroth L, Binquet C, Michel JF, Lefèvre B, Lebeaux D, Lebel J, Dupouy J, Roussillon C, Gimbert A, Wittkop L, Thiébaut R, Orne-Gliemann J, Joseph JP, Richert L, Anglaret X, Malvy D; COVERAGE study group. Duvignaud A, et al. Among authors: richert l. Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1. Trials. 2020. PMID: 33050924 Free PMC article. Clinical Trial.
Pharmacists and the future of cannabis medicine.
Schmitz N, Richert L. Schmitz N, et al. Among authors: richert l. J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):207-211. doi: 10.1016/j.japh.2019.11.007. Epub 2019 Dec 20. J Am Pharm Assoc (2003). 2020. PMID: 31870860
Durable natural killer cell responses after heterologous two-dose Ebola vaccination.
Wagstaffe HR, Susannini G, Thiébaut R, Richert L, Lévy Y, Bockstal V, Stoop JN, Luhn K, Douoguih M, Riley EM, Lacabaratz C, Goodier MR. Wagstaffe HR, et al. Among authors: richert l. NPJ Vaccines. 2021 Jan 29;6(1):19. doi: 10.1038/s41541-021-00280-0. NPJ Vaccines. 2021. PMID: 33514756 Free PMC article.
The use of pore-forming toxins to image lipids and lipid domains.
Tomishige N, Murate M, Didier P, Richert L, Mély Y, Kobayashi T. Tomishige N, et al. Among authors: richert l. Methods Enzymol. 2021;649:503-542. doi: 10.1016/bs.mie.2021.01.019. Epub 2021 Feb 26. Methods Enzymol. 2021. PMID: 33712198
What Makes Thienoguanosine an Outstanding Fluorescent DNA Probe?
Kuchlyan J, Martinez-Fernandez L, Mori M, Gavvala K, Ciaco S, Boudier C, Richert L, Didier P, Tor Y, Improta R, Mély Y. Kuchlyan J, et al. Among authors: richert l. J Am Chem Soc. 2020 Oct 7;142(40):16999-17014. doi: 10.1021/jacs.0c06165. Epub 2020 Sep 23. J Am Chem Soc. 2020. PMID: 32915558 Free PMC article.
269 results